XCath Raises $30 Million to Advance Robotic Surgery Technology
XCath, a Houston-based medical device company specializing in endovascular robotics and steerable neurovascular guidewires, has successfully closed a $30 million Series C funding round. This round was led by Crescent Enterprises, with participation from Dr. Fred Moll, who is also the chairman of the company's board of directors.
Company Overview
XCath focuses on developing next-generation robotic systems designed for precision navigation in complex vascular procedures. The company is particularly noted for its work in neuro-endovascular interventions, aiming to improve the precision and accessibility of treatments involving the brain's blood vessels.
Strategic Use of Funds
The newly acquired capital will be directed towards further development and commercialization of XCath's endovascular surgical robot. A key area of focus is the Iris robotic system, which has been engineered for neurointerventional procedures. According to the company, the Iris system has already been used successfully in first-in-human procedures to treat complex brain aneurysms. These groundbreaking procedures occurred in November 2025 at The Panama Clinic in Panama City.
Advancements in Neurovascular Care
XCath's Iris platform is reportedly the only endovascular robotic system in development capable of achieving intracranial navigation and neurointerventional treatment. The system has demonstrated its capability by performing an intracranial neurovascular procedure involving the robotic manipulation of three devices, using standard monoplane imaging equipment. This technological advancement could facilitate broader adoption in clinical settings, expanding access to specialized neurovascular care globally.
Leadership Insight
Eduardo Fonseca, CEO of XCath, emphasized the importance of this funding round in advancing the company's mission. "We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases," Fonseca said.
Looking Ahead
While XCath's robotic system is still under development and has not yet received clearance for commercial distribution, the company continues to operate from its campuses in Houston, Texas, and Pangyo, South Korea. The focus remains on expanding access to advanced stroke and neurovascular care internationally.
This latest funding round marks a significant step forward in XCath's journey to enhance the capabilities and reach of its robotic technology in the medical field.